New Zealand markets open in 9 hours 34 minutes

Roche Holding AG (RHHBY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
42.00+0.96 (+2.34%)
At close: 03:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close41.04
Open41.63
BidN/A x N/A
AskN/A x N/A
Day's range41.63 - 42.07
52-week range37.88 - 53.86
Volume449,802
Avg. volume1,890,919
Market cap275.806B
Beta (5Y monthly)0.29
PE ratio (TTM)17.87
EPS (TTM)2.35
Earnings dateN/A
Forward dividend & yield1.24 (2.95%)
Ex-dividend date17 Mar 2022
1y target est46.25
  • GlobeNewswire

    Roche launches new diagnostic test for the better understanding of immune response to SARS-CoV-2

    Elecsys IGRA SARS-CoV-2 test supports the better understanding of immune response to SARS-CoV-2 infection or vaccinationThe test detects T-cell response, which may play an important role in determining if immune protection has been achievedThe new diagnostic test may provide clinical care guidance, particularly for immunocompromised and high-risk patient groups Basel, 15 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys® IGRA SARS-CoV-2 test in countries

  • Zacks

    Roche (RHHBY) Influenza Drug Gets FDA Nod for Children

    Roche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.

  • GlobeNewswire

    Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older

    Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age The FDA also approved Xofluza to prevent influenza in children aged five years and older following contact with an infected person Basel, 12 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (balo